BDG SYNTHESIS

Certificate of Analysis

BDG Synthesis certifies that this reference material meets or exceeds the specifications stated herein.

Neil Beare, PhD, Director
16 January 2015

Name: **Rosuvastatin-d_3 Calcium Salt**

CAS Number: 147098-20-2 (unlabelled)

Structure:



Molecular Weight: $2C_{22}H_{24}D_3FN_3O_6S{\cdot}Ca = 1007.17$

Lot Number: BDG 16163.2

Appearance: Off-white, crystalline solid

Corrected Purity: 95.9 % (HPLC) - 0.2 % (methanol) - 2.4 % (water) = 93.3 %

Isotopic Purity: Under 0.5 % d_0

Re-test Date: 16 January 2020

Storage and Handling:

Temperature:	refrigerate for prolonged storage; may be handled and shipped at ambient temperature.
Humidity:	not believed to be hygroscopic; may be handled in normal laboratory atmosphere.
Light:	protect from strong sunlight.
Caution:	only experienced laboratory personnel should handle the material.

Mailing:
BDG Synthesis 2014 Limited
PO Box 38627, Wellington Mail Centre,
Wellington 5045, New Zealand.

Shipping:
BDG Synthesis 2014 Limited
Gracefield Research Centre, Building F,
69 Gracefield Rd, Lower Hutt 5010, New Zealand.

Phone: + 64 4 569 0520
Fax: + 64 4 569 0521

info@bdg.co.nz
www.bdg.co.nz

Identity and Purity

Proton NMR Spectrum

Identity: the signals are consistent with the proposed structure and in accord with literature where available.
Isotopic Labelling: signals at the site of deuteration are absent, compared with what would be expected for unlabelled material, indicating clean deuteration.
Residual Solvents: a small amount of methanol (0.2 % *w/w*) is observed.
Impurities: a trace of an unidentified impurity is seen in the baseline.

Carbon-13 NMR Spectrum

Identity: the signals are consistent with the proposed structure and in accord with literature where available.
Isotopic Labelling: signals at the site of deuteration have collapsed to small multiplets compared with what would be expected for unlabelled material, indicating clean deuteration.

High-resolution Mass Spectrum (ESI+)

Found *m/z* 485.1953. $C_{22}H_{26}D_3FN_3O_6S$ $[M+H]^+$ requires *m/z* 485.1949. The deviation of 0.8 ppm is within normally accepted limits for the establishment of identity by HRMS. No signal for d_0 material was seen (detection limit about 0.5 %).

HPLC

A somewhat broadened, symmetrical peak is observed (95.9 %). Note: in the absence of reference materials for preparing calibration curves, it is assumed that all peaks have the same detector response. Where possible, the conditions of analysis follow a pharmacopeial or literature method, or have been adapted from same.

Elemental Analysis

	Found:	C 51.17, H 5.05, D 1.18, N 8.07 %
$2C_{22}H_{24}D_3FN_3O_6S{\cdot}Ca{\cdot}1.4H_2O$	Requires:	C 51.19, H 4.96, D 1.17, N 8.14 %, H_2O 2.44 %
$2C_{22}H_{24}D_3FN_3O_6S{\cdot}Ca$	Requires:	C 52.47, H 4.80, D 1.20, N 8.34 %

The elemental analyses fall somewhat outside those expected for anhydrous material; the presence of water is reasonably expected from the method of purification and/or the type of material, and the “best-fit” hydrated molecular formula is given. In the absence of a Karl-Fischer water analysis, we recommend that the “best-fit” water content be used when determining corrected purity.

The available quantity of custom-synthesised material is always small, and this limits the extent and type of analytical data which can be obtained. This Certificate is presented in descriptive format for use by analytical chemists who are trained in the use of custom-synthesised materials. Custom materials often contain higher levels of residual solvents and/or water, and we urge you to use the corrected purity where needed rather than the raw HPLC purity. This compound is intended for use as an analytical reference material and it is not for human administration. Structures are shown with relative stereochemistry unless otherwise specified.

The re-test date is assigned from experience gained with the material in the laboratory and/or on storage. It is not possible to perform formal storage studies because of the small amount of material available.

BDG SYNTHESIS

Proton NMR Spectrum of Rosuvastatin-d_3 Calcium Salt in DMSO-d_6

Lot Number: BDG 16163.2



BDG SYNTHESIS

Carbon-13 NMR Spectrum of Rosuvastatin-d_3 Calcium Salt in DMSO-d_6

Lot Number: BDG 16163.2



BDG - Analysis of Rosuvastatin-d3 Calcium

Column : Phenomenex Luna C18(2) 5um 250 x 4.6 mm
Guard : Phenomenex Security Guard C18 RP 4 x 3 mm
Mobile Phase : 55:45 40 mM Formic Acid : Acetonitrile
Flow Rate : 1.0 mL/min
Sample Solvent : Mobile Phase
Column Temperature : 20C
Injection Volume : 10 uL
Detection : UV at 240 nm

Sample Name	BDG 16163.2	**Instrument**	AnalyticalLC01
Acquisition	16/01/2015, 12:30:56	**Method (rev.)**	LC10009c (5)
Sequence	BDG_16Jan2015a	**Vial Position**	2
Operator	solvation010\cerityadmin	**Injection**	1 of 2



Area Percent Report

Peak#	RT	Peak Height	Peak Area	Width	Area %
1	7.49 min	1.6400	30.3934	0.2502 min	0.170 %
2	9.23 min	773.8896	17181.2729	0.3630 min	95.922 %
3	11.64 min	0.8568	10.5354	0.1715 min	0.059 %
4	11.73 min	0.8303	13.3828	0.2020 min	0.075 %
5	13.29 min	10.3827	333.4516	0.4407 min	1.862 %
6	15.09 min	9.5001	333.8397	0.4860 min	1.864 %
7	19.17 min	0.5039	8.9276	0.2207 min	0.050 %